The failure of Amylyx Pharmaceuticals, Inc.’s ALS drug Relyvrio (sodium phenylbutyrate/taurursodiol) in the PHOENIX trial will put the company’s withdrawal pledge to the test in the US.
Key Takeaways
- During advisory committee review, Amylyx had pledged to withdraw Relyvrio if the PHOENIX trial failed.
On 8 March, Amylyx announced that the 664-patient, Phase III PHOENIX trial in amyotrophic lateral sclerosis failed to reach statistical...